MXPA03009936A - Compuestos utiles como intermedios para derivados de 4-aminoquinolina. - Google Patents

Compuestos utiles como intermedios para derivados de 4-aminoquinolina.

Info

Publication number
MXPA03009936A
MXPA03009936A MXPA03009936A MXPA03009936A MXPA03009936A MX PA03009936 A MXPA03009936 A MX PA03009936A MX PA03009936 A MXPA03009936 A MX PA03009936A MX PA03009936 A MXPA03009936 A MX PA03009936A MX PA03009936 A MXPA03009936 A MX PA03009936A
Authority
MX
Mexico
Prior art keywords
intermediates
compounds useful
compounds
useful
Prior art date
Application number
MXPA03009936A
Other languages
English (en)
Inventor
Robert William Scott
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MXPA03009936A publication Critical patent/MXPA03009936A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
    • C07C271/64—Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
MXPA03009936A 2001-04-30 2002-04-08 Compuestos utiles como intermedios para derivados de 4-aminoquinolina. MXPA03009936A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28752201P 2001-04-30 2001-04-30
PCT/IB2002/001217 WO2002088069A2 (en) 2001-04-30 2002-04-08 Compounds useful as intermediates for 4-aminoquinoline derivatives

Publications (1)

Publication Number Publication Date
MXPA03009936A true MXPA03009936A (es) 2004-01-29

Family

ID=23103272

Family Applications (2)

Application Number Title Priority Date Filing Date
MXPA03009935A MXPA03009935A (es) 2001-04-30 2002-04-08 Metodos e intermedios para preparar inhibidores 4-aminoquinolina de cetp.
MXPA03009936A MXPA03009936A (es) 2001-04-30 2002-04-08 Compuestos utiles como intermedios para derivados de 4-aminoquinolina.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MXPA03009935A MXPA03009935A (es) 2001-04-30 2002-04-08 Metodos e intermedios para preparar inhibidores 4-aminoquinolina de cetp.

Country Status (25)

Country Link
US (3) US6689897B2 (es)
EP (2) EP1425270B1 (es)
JP (2) JP3924250B2 (es)
KR (2) KR100639745B1 (es)
CN (3) CN1267411C (es)
AR (3) AR036331A1 (es)
AT (2) ATE316957T1 (es)
AU (1) AU2002253448B2 (es)
BR (2) BR0209238A (es)
CA (2) CA2445623A1 (es)
CZ (2) CZ20032898A3 (es)
DE (2) DE60209004T2 (es)
DK (2) DK1425270T3 (es)
ES (2) ES2259080T3 (es)
HK (1) HK1062294A1 (es)
HU (2) HUP0304039A3 (es)
IL (2) IL157546A0 (es)
MX (2) MXPA03009935A (es)
PL (2) PL366584A1 (es)
PT (1) PT1425270E (es)
RU (2) RU2265010C2 (es)
TW (1) TWI250974B (es)
WO (2) WO2002088085A2 (es)
YU (2) YU84303A (es)
ZA (2) ZA200306599B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US20040002615A1 (en) * 2002-06-28 2004-01-01 Allen David Robert Preparation of chiral amino-nitriles
JP2006021999A (ja) * 2002-07-12 2006-01-26 Kaneka Corp 光学活性β−アミノニトリル化合物およびその対掌体アミド化合物の製造方法
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
MXPA05003456A (es) * 2002-10-04 2005-07-05 Millennium Pharm Inc Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias.
CA2508840A1 (en) 2002-12-20 2004-07-08 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
JP4644658B2 (ja) * 2003-02-18 2011-03-02 高砂香料工業株式会社 光学活性テトラヒドロキノリン類の製造方法
EP1604975A4 (en) * 2003-03-17 2006-11-02 Kaneka Corp PROCESSES FOR PRODUCING (R) -3- 4- (TRIFLUOROMETHYL) -PHENYLAMINO-PENTANAMIDE DERIVATIVES
US7223859B2 (en) 2003-03-17 2007-05-29 Pfizer Inc. Method for producing (R)-3-[4-(trifluoromethyl) phenylamino]-pentanoic acid amide derivative
EP2316447A1 (en) 2003-09-26 2011-05-04 Japan Tobacco, Inc. Method of inhibiting remnant lipoprotein production
PL1670768T3 (pl) * 2003-10-08 2010-01-29 Lilly Co Eli Związki i sposoby leczenia dyslipidemii
CA2543596A1 (en) * 2003-11-07 2005-05-26 Jj Pharma, Inc. Hdl-boosting combination therapy complexes
BRPI0509668A (pt) * 2004-04-07 2007-10-09 Millennium Pharm Inc composto, composição farmacêutica que compreende o mesmo, método de tratamento de enfermidade, distúrbio ou sintoma inflamatório e método de preparação do composto
JP2008504266A (ja) * 2004-06-24 2008-02-14 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物及び方法
DE102004031656A1 (de) * 2004-06-30 2006-01-19 Merck Patent Gmbh Tetrahydrochinoline
WO2006069162A1 (en) * 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
WO2006091674A1 (en) 2005-02-24 2006-08-31 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
US20100041911A1 (en) * 2005-06-20 2010-02-18 Astrazeneca Ab Process For The Production Of (Alkoxycarbonylamino)alkyl Sulfonates
TW200808731A (en) 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives
DE102006031262A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
DE102006031151A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
DE102006032391A1 (de) * 2006-07-04 2008-01-17 Merck Patent Gmbh Fluortenside
DE102006031143A1 (de) * 2006-07-04 2008-01-24 Merck Patent Gmbh Fluortenside
DE102006031149A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
CL2008000684A1 (es) 2007-03-09 2008-08-01 Indigene Pharmaceuticals Inc Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de reductasa hmg-coa; formulacion de dosis unitaria; y uso en el tratamiento de una complicacion diabetica.
JP2011256110A (ja) * 2008-09-30 2011-12-22 Takeda Chem Ind Ltd ヘキサヒドロピロロキノリンの製造法
AR077208A1 (es) * 2009-06-30 2011-08-10 Lilly Co Eli Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
CN103502226B (zh) 2011-04-12 2015-08-19 株式会社钟根堂 用于cetp抑制剂的环烯基芳基衍生物
MX2014000342A (es) * 2011-07-08 2014-05-01 Novartis Ag Metodo para tratar la aterosclerosis en sujetos con alto nivel de trigliceridos.
PT2943474T (pt) 2013-01-31 2017-08-08 Chong Kun Dang Pharmaceutical Corp Compostos biarilo ou biarilo heterocíclico como inibidores de cetp
EA201600255A1 (ru) * 2013-11-11 2016-09-30 Лонца Лтд. Способ получения цианосоединений, содержащих элемент 13 группы, с использованием кислоты льюиса
KR102572626B1 (ko) * 2014-08-12 2023-08-30 뉴암스테르담 파마 비.브이. 테트라하이드로퀴놀린 유도체 제조용의 합성 중간체를 제조하기 위한 방법
CN105294559B (zh) * 2015-06-24 2017-11-14 厦门法茉维特动物药业有限公司 一种医药中间体4‑氨基喹啉类化合物的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE360634T1 (de) 1998-07-10 2007-05-15 Massachusetts Inst Technology Ligande für metalle und verbesserte metall- katalysierte verfahren, die darauf basieren
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines

Also Published As

Publication number Publication date
RU2003131871A (ru) 2005-04-10
WO2002088069A9 (en) 2003-12-04
CZ20032898A3 (cs) 2004-07-14
HUP0304039A2 (hu) 2004-03-29
AR035963A1 (es) 2004-07-28
CA2445693A1 (en) 2002-11-07
ES2256461T3 (es) 2006-07-16
EP1425270A2 (en) 2004-06-09
US20030073843A1 (en) 2003-04-17
KR100639745B1 (ko) 2006-10-30
WO2002088085A2 (en) 2002-11-07
US20020177716A1 (en) 2002-11-28
EP1425270B1 (en) 2006-03-29
KR20040030603A (ko) 2004-04-09
RU2259355C2 (ru) 2005-08-27
US6689897B2 (en) 2004-02-10
KR20040015200A (ko) 2004-02-18
US20030216576A1 (en) 2003-11-20
DE60209004T2 (de) 2006-09-28
JP3924251B2 (ja) 2007-06-06
US6600045B2 (en) 2003-07-29
US6706881B2 (en) 2004-03-16
IL157544A0 (en) 2004-03-28
IL157546A0 (en) 2004-03-28
CN100357265C (zh) 2007-12-26
JP2004531541A (ja) 2004-10-14
CN1297541C (zh) 2007-01-31
YU84303A (sh) 2006-05-25
AR036331A1 (es) 2004-09-01
BR0209238A (pt) 2004-06-15
CZ20032900A3 (cs) 2004-06-16
PL366700A1 (en) 2005-02-07
JP3924250B2 (ja) 2007-06-06
EP1383734A2 (en) 2004-01-28
JP2004527556A (ja) 2004-09-09
RU2003131870A (ru) 2005-01-27
CN1529696A (zh) 2004-09-15
DE60209004D1 (de) 2006-04-13
ZA200306600B (en) 2004-08-25
ZA200306599B (en) 2004-10-22
CN1505609A (zh) 2004-06-16
WO2002088069A3 (en) 2003-02-20
DE60210265T2 (de) 2006-10-12
DK1425270T3 (da) 2006-07-03
ES2259080T3 (es) 2006-09-16
YU84403A (sh) 2006-08-17
WO2002088069A2 (en) 2002-11-07
BR0209291A (pt) 2004-07-13
CN1680292A (zh) 2005-10-12
TWI250974B (en) 2006-03-11
HUP0304041A3 (en) 2005-08-29
HUP0304039A3 (en) 2005-10-28
HU225777B1 (en) 2007-08-28
DE60210265D1 (de) 2006-05-18
EP1383734B1 (en) 2006-02-01
CA2445623A1 (en) 2002-11-07
PT1425270E (pt) 2006-07-31
ATE321755T1 (de) 2006-04-15
AR044706A2 (es) 2005-09-21
RU2265010C2 (ru) 2005-11-27
AU2002253448B2 (en) 2007-07-05
MXPA03009935A (es) 2004-01-29
PL366584A1 (en) 2005-02-07
HK1062294A1 (en) 2004-10-29
HUP0304041A2 (hu) 2004-04-28
DK1383734T3 (da) 2006-05-15
WO2002088085A3 (en) 2004-03-25
ATE316957T1 (de) 2006-02-15
CN1267411C (zh) 2006-08-02
KR100591998B1 (ko) 2006-06-22

Similar Documents

Publication Publication Date Title
MXPA03009936A (es) Compuestos utiles como intermedios para derivados de 4-aminoquinolina.
MXPA03009558A (es) Compuestos novedosos.
GB0105895D0 (en) Novel compounds
AU2002359165A8 (en) Novel compounds
GB0106586D0 (en) Novel compounds
GB0104259D0 (en) Novel compounds
GB0102713D0 (en) Novel compounds
GB0103866D0 (en) Novel compounds
GB0102470D0 (en) Novel compounds
ZA200407363B (en) Novel compounds.
GB0102570D0 (en) Novel Compounds
GB0107389D0 (en) Novel compounds
GB0100181D0 (en) Novel compounds
GB0100182D0 (en) Novel compounds
GB0100184D0 (en) Novel compounds
GB0100185D0 (en) Novel compounds
GB0100186D0 (en) Novel compounds
GB0100187D0 (en) Novel compounds
GB0101334D0 (en) Novel compounds
GB0101437D0 (en) Novel Compounds
GB0102469D0 (en) Novel compounds
GB0100179D0 (en) Novel compounds
GB0102571D0 (en) Novel Compounds
GB0102575D0 (en) Novel Compounds
GB0105095D0 (en) Novel compounds

Legal Events

Date Code Title Description
FG Grant or registration